文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B血液灌流在难治性脓毒性休克中的血流动力学反应及其临床结局:前瞻性队列研究的事后亚组分析

HEMODYNAMIC RESPONSE BY POLYMYXIN B HEMOPERFUSION AND ITS CLINICAL OUTCOMES IN PATIENTS WITH REFRACTORY SEPTIC SHOCK: A POST-HOC SUBANALYSIS OF PROSPECTIVE COHORT STUDY.
PubMed 文献 · Shock · 2025-06-17
一句话结论难治性脓毒性休克患者接受多黏菌素B血液灌流后,65%出现血流动力学反应,反应者28天死亡率8% vs 无反应者31%。

BEAT-SHOCK注册研究为前瞻性队列,纳入309例需大剂量去甲肾上腺素的成人脓毒性休克患者,本预设亚组分析纳入82例接受多黏菌素B血液灌流(PMX-HP)治疗者。血流动力学反应定义为开始PMX-HP后6小时内改良血管加压药依赖指数改善≥20%。53例(65%)出现反应,反应者28天死亡率8%(4/53),无反应者31%(9/29),P=0.0042。SOFA评分≤10、腹腔或尿路感染、开始PMX-HP时改良血管加压药依赖指数≥0.5 mmHg⁻¹三个因素与血流动力学反应相关。

要点

  • 82例难治性脓毒性休克接受PMX-HP者中,53例(65%)在开始后6小时内出现血流动力学反应(改良血管加压药依赖指数改善≥20%)。
  • 反应者28天死亡率8%(4/53),无反应者31%(9/29),P=0.0042。
  • 改良血管加压药依赖指数中位数从开始PMX-HP时0.56 mmHg⁻¹降至6小时后0.34 mmHg⁻¹,中位相对变化-32%。
  • SOFA评分≤10(aOR 3.36)、腹腔或尿路感染(aOR 2.49)、开始PMX-HP时改良血管加压药依赖指数≥0.5 mmHg⁻¹(aOR 2.14)与血流动力学反应相关。
  • 具备上述两个或三个因素的患者更可能出现对PMX-HP的血流动力学反应。

适用人群与场景

  • BEAT-SHOCK注册研究中需大剂量去甲肾上腺素的连续成人脓毒性休克患者309例,本预设亚组分析纳入其中接受PMX-HP治疗的82例。

诊断标准与关键阈值

  • 血流动力学反应定义:开始PMX-HP后6小时内改良血管加压药依赖指数(血管加压药剂量除以平均动脉压)改善≥20%。
  • 与血流动力学反应相关的因素:SOFA评分≤10(aOR 3.36)、腹腔或尿路感染(aOR 2.49)、开始PMX-HP时改良血管加压药依赖指数≥0.5 mmHg⁻¹(aOR 2.14)。

研究设计与关键结果

  • 研究类型:前瞻性队列研究(BEAT-SHOCK注册研究)的预设事后亚组分析,纳入82例接受PMX-HP的难治性脓毒性休克成人患者。
  • 开始PMX-HP时改良血管加压药依赖指数中位数0.56 mmHg⁻¹,6小时后0.34 mmHg⁻¹,中位相对变化-32%。
  • 血流动力学反应者53例(65%),无反应者29例(35%)。
  • 28天死亡率:反应组8%(4/53) vs 无反应组31%(9/29),P=0.0042。
  • 与血流动力学反应相关的因素:SOFA评分≤10(aOR 3.36)、腹腔或尿路感染(aOR 2.49)、开始PMX-HP时改良血管加压药依赖指数≥0.5 mmHg⁻¹(aOR 2.14);具备两个或三个因素者更可能出现反应。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究的预设事后亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在难治性脓毒性休克接受PMX-HP的患者中,开始后6小时内改良血管加压药依赖指数改善≥20%者28天死亡率较低(8% vs 31%)。
  • SOFA评分≤10、腹腔或尿路感染、开始PMX-HP时改良血管加压药依赖指数≥0.5 mmHg⁻¹三个因素的数量与血流动力学反应可能性相关,具备两个或三个因素者更可能出现反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Polymyxin B hemoperfusion (PMX-HP) reportedly improves hemodynamic status in some but not all patients with septic shock. We examined the association between hemodynamic response and clinical outcomes and explored factors that may identify patients with hemodynamic response. Methods: BEAT-SHOCK registry is a prospective cohort study of 309 consecutive adult patients with septic shock requiring high-dose norepinephrine. This predefined subanalysis included 82 patients treated with PMX-HP. We defined hemodynamic response as a ≥ 20% improvement within 6 h of starting PMX-HP in the modified vasopressor dependency index, representing vasopressor dosage divided by mean arterial pressure. Results: The median modified vasopressor dependency index at the start of PMX-HP was 0.56 mmHg -1 , and 0.34 mmHg -1 6 h after starting PMX-HP (median relative change -32%). Hemodynamic response was obtained in 53 patients (65%; responder group). The 28-day mortality rate was 8% (4/53) in the responder group and 31% (9/29) in the nonresponder group ( P = 0.0042). Three potential factors were: lower Sequential Organ Failure Assessment score (≤10, adjusted odds ratio [aOR] 3.36), abdominal or urinary tract infection (aOR 2.49), and higher modified vasopressor dependency index at the start of PMX-HP (≥0.5 mmHg -1 , aOR 2.14). Patients with two or three factors were likely to respond to PMX-HP. Conclusions: Among patients with refractory septic shock, 65% had hemodynamic response after PMX-HP, and it was associated with better clinical outcomes, as shown by the higher survival rate. The number of the following factors was associated with the likelihood of hemodynamic response: less organ dysfunction, more vasopressors, and abdominal/urinary tract infection. Trial registration: UMIN Clinical Trial Registry on 1 November 2019 (registration no. UMIN000038302).

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Miyamoto K, Kawazoe Y, Miyagawa N, et al. HEMODYNAMIC RESPONSE BY POLYMYXIN B HEMOPERFUSION AND ITS CLINICAL OUTCOMES IN PATIENTS WITH REFRACTORY SEPTIC SHOCK: A POST-HOC SUBANALYSIS OF PROSPECTIVE COHORT STUDY. Shock. 2025. PMID: 40550704. doi:10.1097/SHK.0000000000002654

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。